BayVax Biotech leverages cutting-edge AI models to predict immune responses, design novel antigens, and accelerate the development of personalized and broad-spectrum vaccines.
Our proprietary models surpass traditional methods by simulating biological systems with up-to-date AI architecture
Cross-attention mechanisms simulate peptide-MHC-TCR binding to predict immunogenicity beyond traditional algorithms.
View Webserver→TCR generator can create TCR sequences targeting hotspot mutations with high positive rate.
End-to-end solutions from HLA typing to epitope prediction and generative design.
Proven efficacy in investigator-initiated trial with promising progression-free survival extension.
From research to clinical implementation
Commercialize digital pipelines through licensing and partnerships.
Patient-specific neoantigen sequences for solid tumors with significantly extended PFS.
AI-designed antigens for infectious diseases with enhanced cross-reactivity.
Validating our AI models through rigorous research
Pipelines
| Vaccine Type | Prototype | In-silico Study | Animal Study | IND-enabling |
|---|---|---|---|---|
| Neoantigen Cancer Vaccine | Peptide | IIT | ||
| Pan-coronavirus Vaccine | Viral Vector | |||
| Senolytic(Anti-aging) Vaccine | Protein | |||
| Autoimmune Disease Vaccine | Peptide |
Regulatory pathway opened for neoantigen vaccines following first FDA approval.
Investigator-initiated trials at HKU-Shenzhen Hospital show promising PFS extension.
Previous IITs in solid tumours (HCC, MSS-CRC) showed significantly extended PFS.
Our latest scientific contributions to immunology and vaccine development
Collaborate on IND applications, licensing, or co-development
admin@bayvaxbio.com
+852 5615 7942
15221876358
Shenzhen, China
Hong Kong, China
The Results of Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine Has been Released on June 13, 2025. Pharmaron is recommended as the preferred partner for this project.
The public notice period is from June 13, 2025 to June 17, 2025.
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
The tender announcement was officially released on May 14, 2025. By the deadline of June 6, 2025, bid documents from three qualified vendors were received and shortlisted for in-depth evaluation. As of June 13, 2025 the results of this tender has been released.
Pharmaron Beijing Co., Ltd. is recommended as the preferred partner for this project.
| Rank | Vendors | Score |
|---|---|---|
| 1 | Pharmaron Beijing Co., Ltd. 康龙化成（北京）新药技术股份有限公司 |
93.67 |
| 2 | Vender 2 | 87.67 |
| 3 | Vender 3 | 74.33 |
The public notice period is from June 13, 2025 to June 17, 2025.
If a bidder or any other interested party has an objection to the bid evaluation results, they must submit a written objection to the tendering entity during the public notice period. The tendering entity will provide a written response within three (3) days of receiving the objection. Bidding activities will be suspended until a response is issued.
If the bidder or interested party remains dissatisfied with the tendering entity’s response, they may file a formal complaint with the relevant industry regulatory authority or public resource trading supervision agency within ten (10) days of receiving the response. The complaint must include the tendering entity’s reply and a written complaint letter.
| Project Title | Preclinical Toxicity Study for Peptide-Based Neoantigen Cancer Vaccine |
| Reference No | TOX-2025-001 |
| Budget | Not exceeding HKD 1,500,000 |
| Deadline | June 6, 2025 |
We seek qualified Contract Research Organizations (CROs) to conduct an IND-enabling toxicity study for a peptide-based neoantigen cancer vaccine. This study is critical to support Investigational New Drug (IND) applications to the Center for Drug Evaluation (CDE) in China and the U.S. Food and Drug Administration (FDA).
The selected CRO must deliver:
| Criterion | Weight |
|---|---|
| Scientific & Technical Merit | 40% |
| Regulatory Compliance | 30% |
| Cost-Effectiveness | 20% |
| Past Performance | 10% |
Note: Proposals exceeding the budget cap will be disqualified. Inquiries must be submitted by June 10, 2025.